Edwards Lifesciences Corp (EW) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Total Assets Chart for Edwards Lifesciences Corp
Edwards Lifesciences Corp (EW) total assets for FY2025 were USD 13.7B, a 4.9% change from FY2024. Edwards Lifesciences Corp's total assets grew from USD 1.4B in 1999 to USD 13.7B in 2025 (853.2% over 26 years). Total assets compound annual growth rate: 5-year CAGR of 13.6%, 10-year CAGR of 12.9%, 20-year CAGR of 12.8%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $51.43B
- Implied Share Price
- $89.32
- Enterprise Value
- $48.04B
- Revenue (TTM)
- $6.51B
- EBITDA
- $2.00B
- Profit Margin
- 15.43%
- Trailing P/E
- 53.17
- Forward P/E
- 29.85
- Price/Book (MRQ)
- 4.86
- Price/Sales (TTM)
- 7.91
- EV/EBITDA
- 29.08
- EV/Revenue
- 7.38
- Dividend Yield
- —
- Book Value
- $17.90
- Free Cash Flow (FY2025)
- $1.33B
- Free Cash Flow Yield
- 2.60%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.